DelveInsight Business Research LLP

Peripheral T-Cell Lymphoma Overview

Peripheral T-cell lymphomas (PTCLs) are an uncommon and heterogeneous group of clinically aggressive types of non-Hodgkin lymphoma (NHL) that develop in mature white blood cells called “T cells” and “natural killer (NK) cells.” It is Peripheral T- Cell Lymphoma’s origin in the lymphatic system that gave it the name peripheral T-cell lymphoma. In the case of PTCL, the term “peripheral” does not refer to the extremities, but identifies PTCL as cancer that arises in the lymphoid tissues outside of the bone marrow such as lymph nodes, spleen, gastrointestinal tract, and skin. Signs and symptoms of Peripheral T- Cell Lymphoma include asymptomatic lymphadenopathy, Fever, night sweats, poor appetite, and weight loss including fatigue, and painless swelling in the neck, armpit, or groin (due to an enlarged lymph node). Different staging systems have been proposed for Peripheral T- Cell Lymphomas.

Peripheral T-Cell Lymphoma Epidemiology Insights

• The total Peripheral T-cell Lymphoma market size in the 7MM is USD 564 million in 2021 and is projected to grow during the forecast period (2022-2032).

• The total incident population of Peripheral T- Cell Lymphomas in the 7MM comprised of 18,027 cases in 2021 and is projected to increase during the forecast period.

• The total Peripheral T- Cell Lymphomas market size in the United States is expected to increase with a CAGR of 4.9% during the study period (2019–2032).

Click here to learn more about the Peripheral T-Cell Lymphoma Market Landscape

The Report Covers the Peripheral T-Cell Lymphoma Epidemiology Segmented by:

• Total Peripheral T-Cell Lymphoma incident cases 

• Total Peripheral T-Cell Lymphoma prevalent cases 

• Total Peripheral T-Cell Lymphoma diagnosed cases 

• Total Peripheral T-Cell Lymphoma treatment cases 

Peripheral T-Cell Lymphoma Market Outlook 

The therapeutic challenge for Peripheral T- Cell Lymphoma remains as these are aggressive and rare cancers which are extremely diverse. To make matters worse, it remains a disease with a poor prognosis and limited treatment options, especially in comparison to its B-cell counterparts. The existing treatment options for Peripheral T- Cell Lymphoma include CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone), which emerged as the standard of care in the treatment of aggressive non-Hodgkin lymphomas in the 1990s when the distinction between peripheral T-cell lymphoma and aggressive B-cell-derived non-Hodgkin lymphoma became apparent. The treatment options for Peripheral T- Cell Lymphoma include combination chemotherapy regimens typically CHOP-based chemotherapy or EPOCH (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone), localized radiotherapy, stem cell transplants, and steroid therapy.

 Key Companies Working in the Peripheral T-Cell Lymphoma Market

•  Pfizer 

•  Huya Biosciences International

•  Solasia Pharmaceuticals 

•  Acrotech Biopharmaceuticals 

•  Takeda 

•  Viracta Pharmaceuticals 

And many others

 Peripheral T-Cell Lymphoma Therapies Covered and Analyzed in the Report:-

• XALKORI (crizotinib)

• HIYASTA (tucidinostat)

• DARVIAS (darinaparsin)

• BELEODAQ (belinostat)

• ADCETRIS (brentuximab vedotin)

• Nanatinostat

And many others 

Learn more about the Key Companies and Emerging Therapies in the Peripheral T-Cell Lymphoma Market

Table of Contents 

1. Key Insights 

2. Peripheral T-Cell Lymphoma  Introduction 

3. Executive Summary of Peripheral T-Cell Lymphoma       

4. Disease Background and Overview

5. Epidemiology and patient population

6. Peripheral T-Cell Lymphoma Emerging Therapies

7. Peripheral T-Cell Lymphoma Market Outlook

8. Market Access and Reimbursement of Therapies

9. Market Drivers 

10. Market Barriers 

11. Appendix

12. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

Learn about the detailed offerings of the report @ Peripheral T-Cell Lymphoma Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services